Select Page

Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design

Volume 9, Issue 5   May 2013
Keywords: Emerging Infectious Diseases, H7N9, Immunoinformatics, Influenza, T Cell Epitope, Vaccine, Vaccine Design

Authors: Anne S. De Groot, Matthew Ardito, Frances Terry, Lauren Levitz, Ted Ross, Leonard Moise and William Martin

Abstract: 

A new avian-origin influenza virus emerged near Shanghai in February 2013, and by the beginning of May it had caused over 120 human infections and 26 deaths. Human-to-human transmission of avian-origin H7N9 influenza A has been limited to a few family clusters, but the high mortality rate (20%) associated with human infection has raised concern about the potential for this virus to become a significant human pathogen. European, American, and Asian vaccine companies have already initiated the process of cloning H7 antigens such as hemagglutinin (HA) into standardized vaccine production vehicles. Unfortunately, previous H7 HA-containing vaccines have been poorly immunogenic. We used well-established immunoinformatics tools to analyze the H7N9 protein sequences and compare their T cell epitope content to other circulating influenza A strains as a means of estimating the immunogenic potential of the new influenza antigen. We found that the HA protein derived from closely related human-derived H7N9 strains contain fewer T cell epitopes than other recently circulating strains of influenza, and that conservation of T cell epitopes with other strains of influenza was very limited. Here, we provide a detailed accounting of the type and location of T cell epitopes contained in H7N9 and their conservation in other H7 and circulating (A/California/07/2009, A/Victoria/361/2011, and A/Texas/50/2012) influenza A strains. Based on this analysis, avian-origin H7N9 2013 appears to be a “stealth” virus, capable of evading human cellular and humoral immune response. Should H7N9 develop pandemic potential, this analysis predicts that novel strategies for improving vaccine immunogenicity for this unique low-immunogenicity strain of avian-origin influenza will be urgently needed.

Full Text Here

Received: April 30, 2013; Accepted: May 4, 2013; Published Online: May 1, 2013

See EpiVax’s H7N9 blog posts and slide deck below:

Questions? Want more info?
Anthony Marcello
BDA EpiVax, inc.
Email Us Here.